“The Corona crisis triggered the largest collective educational push to use digital tools ever.”Thomas Erkinger EOSS CEO Thomas Erkinger talks about our life science focus, high innovation density and reindustrialization…
read more
Since the beginning of April, EOSS Technologies has been the largest shareholder in the Austrian drug producer Sanochemia Pharmazeutika, with a stake of just under 50%. After intensive negotiations, a…
read more
Genspeed Biotech is developing the first COVID19 point-of-care assay that allows both infected and recovered patients to be tested in a single run in just minutes. The development of the…
read more
EOSS Technologies is supporting the government in Montenegro in the extensive measures to combat the Corona pandemic. With a donation of 20,000 € for the purchase of a vital intensive…
read more
Some two billion possible agents are going to be tested during the world’s largest computer-aided screening project. Styrian research is again attracting international attention with its research on the coronavirus:…
read more
The search for effective drugs against the coronavirus is ongoing worldwide – also in the BSL3 high-security laboratory in Graz. Thick protective suits, safety locks and disinfectant showers are the…
read more
Increasingly sophisticated applications of artificial intelligence dominate everyday life and industry. Styrian magazine Spirit of Styria explains why AI is the gold of digitalization and how Innophore’s AI algorithm for…
read more
With “Drug and Enzyme Discovery” the Styrian start-up Innophore has already gained attention outside the European borders in recent years. Innophore has now also made its knowledge available to the…
read more
In the context of the COVID-19 pandemic, EOSS companies in the Lifescience division are playing an increasingly important role internationally. Accordingly, the media attention is also high. With Sanochemia, Innophore,…
read more
Sanochemia is to contribute to the security of supply of pharmaceuticals in the future. According to Thomas Erkinger, this requires a pharmaceutical strategy from policymakers that involves small and medium-sized…
read more
